Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells

Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells

Background: The relevance of the cancer immune cycle in therapy response implies that successful treatment may trigger the exposure or the release of immunogenic signals. Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (...

Full description

Bibliographic Details
Main Authors: Lucía Villamañan, Laura Martínez-Escardó, Carles Arús, Victor J. Yuste, Ana P. Candiota
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
preclinical glioblastoma
cancer immune cycle
immunogenic signals
calreticulin
ATP
protein kinase CK2
Online Access:https://www.mdpi.com/1422-0067/22/7/3453

Internet

https://www.mdpi.com/1422-0067/22/7/3453

Similar Items